Success Metrics

Completion Rate
0%(0/1)
Active Trials
3(43%)
Terminated
1(14%)

Phase Distribution

Ph phase_1
1
14%
Ph phase_2
5
71%

Phase Distribution

1

Early Stage

5

Mid Stage

0

Late Stage

Phase Distribution6 total trials
Phase 1Safety & dosage
1(16.7%)
Phase 2Efficacy & side effects
5(83.3%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

0.0%

0 of 2 finished

Non-Completion Rate

100.0%

2 ended early

Currently Active

3

trials recruiting

Total Trials

7

all time

Status Distribution
Active(3)
Terminated(2)
Other(2)

Detailed Status

unknown2
Active, not recruiting2
Withdrawn1
Recruiting1
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
7
Active
3
Success Rate
0.0%
Most Advanced
Phase 2

Trials by Phase

Phase 11 (16.7%)
Phase 25 (83.3%)

Trials by Status

withdrawn114%
recruiting114%
terminated114%
unknown229%
active_not_recruiting229%

Recent Activity

3 active trials
Showing 5 of 7
active_not_recruiting

UK ENcorafenib and BInimetinib Real-world Study in Melanoma

NCT07022457
recruitingphase_2

Encorafenib and biNimetinib Followed by CEmiplimab and FiAnLimab in Patients With BRAF Mutant melanOma and Symptomatic Brain Metastases

NCT06887088
active_not_recruitingphase_2

Immunotherapy With Ipilimumab and Nivolumab Preceded or Not by a Targeted Therapy With Encorafenib and Binimetinib

NCT03235245
terminatedphase_2

StrataPATH™ (Precision Indications for Approved Therapies)

NCT05097599
unknownphase_2

(Neo)Adjuvant BRAF/MEK Inhibition in pN1c Melanoma

NCT05767879
View all 7 trials

Clinical Trials (7)

Showing 7 of 7 trials
NCT07022457

UK ENcorafenib and BInimetinib Real-world Study in Melanoma

Active Not Recruiting
NCT06887088Phase 2

Encorafenib and biNimetinib Followed by CEmiplimab and FiAnLimab in Patients With BRAF Mutant melanOma and Symptomatic Brain Metastases

Recruiting
NCT03235245Phase 2

Immunotherapy With Ipilimumab and Nivolumab Preceded or Not by a Targeted Therapy With Encorafenib and Binimetinib

Active Not Recruiting
NCT05097599Phase 2

StrataPATH™ (Precision Indications for Approved Therapies)

Terminated
NCT05767879Phase 2

(Neo)Adjuvant BRAF/MEK Inhibition in pN1c Melanoma

Unknown
NCT04759846Phase 1

Hepatic Impairment Study of Encorafenib in Combination With Binimetinib in BRAF Melanoma

Withdrawn
NCT05097378Phase 2

Perioperative Encobini in BRAFV600 Mutant Stage III (B/C/D) or Oligometastatic Stage IV Melanoma

Unknown

All 7 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
7